Oasis Fertility, Hyderabad, India.
Gynecol Endocrinol. 2021 Jun;37(6):515-518. doi: 10.1080/09513590.2020.1793941. Epub 2020 Jul 15.
This study was done to compare the efficacy of transdermal estrogen (gel) to oral estradiol in hormone replacement frozen embryo transfer cycles (HR- FET).
This was a prospective study conducted between March 2019 and December 2019. We included 294 HR FET cycles: 156 cycles using oral estrogen tablets (oral group) and 138 cycles using transdermal gel (17 beta estradiol 0.06% w/w) (gel group). Primary objective of this study was to compare endometrial thickness (ET) on the day of progesterone start between the two groups. Our secondary objective was to compare implantation rates (IR), clinical pregnancy rates (CPR), miscarriage rates (MR), duration of estrogen administration, estradiol (E2) levels before the start of progesterone, cycle cancellation rates, patient satisfaction score and undesirable side effects between both the groups.
There was no significant difference in the ET, IR, CPR, MR and duration of E2 administration and cycle cancellation rates between both the groups. Patient satisfaction score was significantly higher (8.02 ± 1.07 vs 6.96 ± 0.99 < .01) and side effects were significantly lower (18.1% vs 55.1%, ≤.01), in the gel group compared to the oral group.
This study concluded that transdermal estrogen (gel) is equally efficacious as oral estrogen in HR FET cycles with transdermal gel having an added benefit of better patient comfort with less side effects and better safety profile.
本研究旨在比较经皮雌激素（凝胶）与口服雌二醇在激素替代冻融胚胎移植周期（HR-FET）中的疗效。
这是一项前瞻性研究，于 2019 年 3 月至 2019 年 12 月进行。共纳入 294 例 HR-FET 周期：156 例使用口服雌激素片（口服组），138 例使用经皮凝胶（17β雌二醇 0.06%w/w）（凝胶组）。本研究的主要目的是比较两组患者在开始使用孕激素当天的子宫内膜厚度（ET）。次要目的是比较两组患者的种植率（IR）、临床妊娠率（CPR）、流产率（MR）、雌激素给药时间、开始使用孕激素前的雌二醇（E2）水平、周期取消率、患者满意度评分和不良反应。
两组患者的 ET、IR、CPR、MR 和 E2 给药时间以及周期取消率无显著差异。与口服组相比，凝胶组患者的满意度评分显著更高（8.02±1.07 比 6.96±0.99，<.01），不良反应显著更少（18.1%比 55.1%，<.01）。
本研究表明，经皮雌激素（凝胶）与口服雌激素在 HR-FET 周期中同样有效，经皮凝胶具有更好的患者舒适度、更少的不良反应和更安全的特性。
